Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy
Series: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy; 5;
- Publisher's listprice EUR 154.00
-
65 326 Ft (62 216 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 6 533 Ft off)
- Discounted price 58 794 Ft (55 994 Ft + 5% VAT)
65 326 Ft
Availability
Uncertain availability. Please turn to our customer service.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Academic Press
- Date of Publication 1 November 2024
- ISBN 9780128229149
- Binding Hardback
- No. of pages250 pages
- Size 234x191 mm
- Language English 0
Categories
Long description:
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy discusses current and under investigation treatments in pancreatic cancer. The book presents information on how to combine current therapy with treatment under development and/or in clinical trials in order to improve survival. Chapters review new modalities to cure oncolytic viruses and Bi-specific T cell engager (BiTEs) as future clinical treatments, along with discussions on recent research using those modalities in combination therapy. The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about new therapies.
- Discusses oncolytic virus in pancreatic cancer use, mainly herpes and adenoviruses, the results obtained on basic research, and clinical trials
- Encompasses knowledge on Bi-specific T cell engager (BiTEs), focusing on its function, development and use on pancreatic cancer
- Brings information on recently developed combination therapies that allow for a lower dose of treatment and hence less side effects
Table of Contents:
1. Pancreatic cancer generalities, current surgical treatment, updates
2. Current chemotherapy and immunotherapy in pancreatic cancer
3. Generalities of Oncolytic virus and HF10 in pancreatic cancer
4. Oncolytic Adenovirus use in pancreatic cancer
5. BiTE cell generalities and its potential use for pancreatic cancer
6. Precision oncology for pancreatic cancer
7. Strategies with immune therapy
8. Combination therapies of current/ new options to treat pancreatic cancer in future
Chances: And How To Take Them
Subcribe now and receive a favourable price.
Subscribe
7 362 HUF
Phoenicians and the Making of the Mediterranean
Subcribe now and receive a favourable price.
Subscribe
10 602 HUF
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy
Subcribe now and receive a favourable price.
Subscribe
65 326 HUF
